Get your free personalized podcast brief

We scan new podcasts and send you the top 5 insights daily.

When pioneering a therapy in a disease without precedent approvals, regulatory agencies operate on draft guidance. Drawing on his past work at Madrigal developing the first MASH therapy, Kia Motesharei emphasizes that sponsors must proactively engage regulators years ahead of commercialization. High unmet medical needs in rare indications grant agencies regulatory flexibility, allowing companies to collaborate with the FDA to define acceptable surrogate endpoints and approval pathways.

Related Insights

Early-stage biotechs with limited funds must balance the need for quick data with building a solid IND package. The solution is to run two tracks in parallel: one for immediate R&D experiments and another dedicated to the methodical, long-term planning required for regulatory submission.

Companies developing therapies with novel components like membrane proteins must navigate CMC development without established regulatory guidance. Unlike well-understood biologics like monoclonal antibodies, the lack of precedent in databases creates unique challenges for defining processes and satisfying regulatory bodies, requiring pioneers to set the standards.

For rare diseases without established clinical endpoints, biotech firms should co-design new endpoints with patients and their families. Presenting these patient-centric measures to the FDA builds a bond of trust and provides the agency with a clear, meaningful rationale for drug approval.

When developing a novel platform with no regulatory precedent, the key is to present a robust scientific case to agencies. This involves educating them with comprehensive data and explaining the 'why' behind your approach, rather than simply trying to fit into existing guidelines that may not apply.

The value of a late-stage asset is not just its scientific promise. Acquirers and investors look for a clear definition of unmet medical need, a straightforward clinical development pathway, and a well-defined regulatory landscape to de-risk the path to market.

Instead of viewing regulatory affairs as a final compliance hurdle, involve them at the earliest stages. Their input on market needs and application can strategically shape the drug's design and development process, distinguishing a mere "drug" from a viable "product."

The successful use of a surrogate endpoint (proteinuria reduction) for IgA nephropathy approvals has created a clear regulatory pathway. This blueprint is now being leveraged by developers to advance therapies for other previously untreatable renal diseases like FSGS, de-risking their clinical programs.

After a program achieves Breakthrough or RMAT status, the FDA's engagement model changes significantly. The agency becomes a collaborative partner, with regulatory project managers proactively reaching out for data updates to provide real-time guidance and facilitate more efficient drug development.

While the FDA's new "plausible mechanism framework" is officially for bespoke, N-of-one therapies, experts at its rollout expressed an expectation that its principles could be applied more broadly. This suggests a potential new pathway for other rare diseases, moving beyond an ultra-rare scope.

Following public pressure, the FDA seems to be entering a "kinder, gentler" era for orphan drugs. Reports indicate agency leaders are proactively meeting with companies post-rejection to find a path forward. This suggests a potential shift towards more flexibility for therapies in rare diseases with high unmet need, even with imperfect data.

Developing First-Ever Indications Requires Co-Creating Regulatory Roadmaps Alongside Clinical Execution | RiffOn